Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects

Clinical Therapeutics
Akiko SarashinaK A Dugi

Abstract

The dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is in clinical development for the treatment of type 2 diabetes mellitus (T2DM). In previous studies in non-Japanese populations, linagliptin showed potential as a once-daily oral antidiabetic drug. This study investigated the tolerability, pharmacokinetics, and pharmacodynamics of linagliptin in healthy adult male Japanese volunteers, in compliance with Japanese regulatory requirements for new drugs intended for use in humans. This was a Phase I, randomized, doubleblind, placebo-controlled study in healthy volunteers. Linagliptin or placebo was administered as single escalating doses of 1, 2.5, 5, and 10 mg, or as multiple escalating doses of 2.5, 5, and 10 mg once daily for 12 days. Three quarters of subjects in each dose group were randomized to active drug and one quarter to placebo. Blood and urine samples for determination of pharmacokinetic parameters were obtained before administration of the first dose of study drug and at regular time points after administration, with more frequent blood sampling on days 1 and 12 in subjects receiving multiple doses. Inhibition of DPP-4 activity and plasma concentrations of glucagon-like peptide-1 (GLP-1) and glucose were also d...Continue Reading

References

Sep 26, 1997·Statistics in Medicine·S Senn
Dec 1, 1999·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·G T KoJ Woo
Oct 12, 2000·Diabetes Research and Clinical Practice·K Matsuoka
Sep 27, 2002·Diabetes/metabolism Research and Reviews·Ryuzo Kawamori
Sep 30, 2003·Diabetes Care·Daniel J Drucker
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Aug 28, 2004·Diabetes·Carolyn F Deacon
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Apr 5, 2007·Current Medical Research and Opinion·Richard E Pratley, Afshin Salsali
Dec 14, 2007·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·U LaufsM Böhm
May 14, 2008·Journal of Endocrinological Investigation·D PitoccoR Gentilella
Aug 13, 2008·Diabetes Care·Maria C E RossiUNKNOWN Associazione Medici Diabetologi Annals Study Group
Nov 7, 2008·The Tohoku Journal of Experimental Medicine·Naoki KohFumio Chino
Jan 6, 2009·Diabetes Care·UNKNOWN American Diabetes Association
Jun 30, 2009·Biopharmaceutics & Drug Disposition·Holger FuchsAndreas Greischel
Dec 2, 2009·Expert Opinion on Investigational Drugs·Carolyn F Deacon, Jens J Holst
Jan 9, 2010·Cleveland Clinic Journal of Medicine·Lawrence Blonde
Jan 21, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechKlaus Wagner
Sep 1, 1999·Asia Pacific Journal of Clinical Nutrition·M Deurenberg-YapW A VAN Staveren

❮ Previous
Next ❯

Citations

Apr 14, 2012·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Tsuyoshi OhmuraJeffrey Encinas
Mar 30, 2011·Drugs·Lesley J Scott
May 10, 2012·Clinical Pharmacokinetics·Ulrike Graefe-ModyChristian Friedrich
May 14, 2014·Regulatory Peptides·Vladimer DarsaliaCesare Patrone
Jul 19, 2013·BioMed Research International·Tianhong GuYuhui Zhang
Feb 3, 2012·Expert Opinion on Pharmacotherapy·Marc RendellRadha Andukuri
Feb 5, 2013·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Oct 26, 2011·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Apr 20, 2011·Expert Opinion on Investigational Drugs·Baptist Gallwitz
Apr 22, 2014·Expert Opinion on Drug Metabolism & Toxicology·Theodosios D FilippatosMoses S Elisaf
Mar 24, 2012·Clinical Therapeutics·Joshua J Neumiller, Stephen M Setter
Nov 21, 2012·Diabetes, Obesity & Metabolism·E ArakiH-J Woerle
Jan 22, 2013·British Journal of Clinical Pharmacology·Christian FriedrichHans-Juergen Woerle
Jan 19, 2019·Applied Microbiology and Biotechnology·Tina Vida Plavec, Aleš Berlec
Jan 11, 2020·Luminescence : the Journal of Biological and Chemical Luminescence·Heba A ArefKhaled M Darwish
Jun 13, 2012·Clinical Pharmacokinetics·Larry K GolightlyMichael T McDermott
Jun 12, 2013·Postgraduate Medicine·George Grunberger
Jun 8, 2019·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Zhong-Ping GouPing Feng

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.